EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Interplay Between the Mineralocorticoid System, Inflammation, Hypertension, and Kidney Disease

Eviatar Fields iD, Ernesto L Schiffrin iD

Kidney360 · 2025-11 · 6 (11) · 2017-2027

DOI: 10.34067/kid.0000000929 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney360, online erschienen am 22.07.2025. Verfasst von Eviatar Fields und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Hypertension, Inflammation, Aldosterone, Kidney Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institute of Circulatory and Respiratory Health, McGill University, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aldosterone, produced by adrenal glomerulosa cells, stimulated by angiotensin II, adrenocorticotrophin, and potassium, and inhibited by natriuretic peptides, plays a role in hypertension and CKD development and progression. Its effects are mediated by nuclear mineralocorticoid receptors inducing genomic effects and putatively by a membrane G-protein–coupled receptor which could be the G-protein–coupled estrogen receptor, triggering nongenomic actions. The classical effect of aldosterone is on the distal nephron to retain Na + and water and excrete potassium, contributing to electrolyte and extracellular volume control. However, aldosterone also acts by stimulating oxidative stress through different signaling pathways that include tyrosine kinases and mitogen-activated protein kinases to induce inflammation and fibrosis in blood vessels, the kidney, and the heart. The actions of aldosterone also lead to endothelial dysfunction, which participates in its effects on target organs, including progression of hypertension. Blockade of mineralocorticoid receptor or inhibition of aldosterone generation lowers BP and protects target organs, reducing progression of CKD. All these actions are reviewed, with an emphasis on the effects on the kidney.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionInflammationAldosteroneKidney DiseasesKidneyMineralocorticoidsHumansReceptors, MineralocorticoidAnimalsSignal Transduction

Stichwörter der Autor:innen

CKDaldosteroneangiotensincardiovascular diseasechronic inflammationhypertensionimmunologylymphocytesmacrophagesvascular disease

Substanzen

AldosteroneReceptors, MineralocorticoidMineralocorticoids

Autor:innen und Institutionen

  • Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.
  • Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.

ORCID-Profile: Eviatar Fields, Ernesto L Schiffrin

Förderung

  • Institute of Circulatory and Respiratory Health
  • McGill University
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Fields, E., & Schiffrin, E. L. (2025). Interplay Between the Mineralocorticoid System, Inflammation, Hypertension, and Kidney Disease. Kidney360, 6(11), 2017-2027. https://doi.org/10.34067/kid.0000000929

Vancouver

Fields E, Schiffrin EL. Interplay Between the Mineralocorticoid System, Inflammation, Hypertension, and Kidney Disease. Kidney360. 2025;6(11):2017-2027. doi:10.34067/kid.0000000929

BibTeX
@article{Fields2025,
  author = {Fields, Eviatar and Schiffrin, Ernesto L},
  title = {Interplay Between the Mineralocorticoid System, Inflammation, Hypertension, and Kidney Disease},
  journal = {Kidney360},
  year = {2025},
  volume = {6},
  number = {11},
  pages = {2017--2027},
  doi = {10.34067/kid.0000000929}
}
Kostenlos starten →